Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2004-01

AUTHORS

L E Diamond, D C Earle, R C Rosen, M S Willett, P B Molinoff

ABSTRACT

PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan™ in healthy subjects without visual sexual stimulation (VSS) and in Viagra®-responsive ED patients with VSS. In healthy subjects, mean Cmax and AUC(0–t) increased in a dose-dependent manner. Median Tmax was 0.50 h and mean t1/2 ranged from 1.85 to 2.09 h. In both studies, an erectile response induced by PT-141 administration was statistically significant, compared to placebo, at doses greater than 7 mg, with the onset of the first erection occurring in approximately 30 min. PT-141 was safely administered and well tolerated in both studies. A maximum-tolerated dose was not identified. Flushing and nausea were the most common adverse events reported in both studies and no clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed. Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED. More... »

PAGES

51-59

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.ijir.3901139

DOI

http://dx.doi.org/10.1038/sj.ijir.3901139

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1039312960

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/14963471


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Administration, Intranasal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Erectile Dysfunction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Penile Erection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Peptides, Cyclic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Placebos", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Melanocortin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Severity of Illness Index", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "alpha-MSH", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Palatin Technologies, Inc., Cranbury, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.423353.0", 
          "name": [
            "Palatin Technologies, Inc., Cranbury, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diamond", 
        "givenName": "L E", 
        "id": "sg:person.0762637112.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762637112.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Palatin Technologies, Inc., Cranbury, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.423353.0", 
          "name": [
            "Palatin Technologies, Inc., Cranbury, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Earle", 
        "givenName": "D C", 
        "id": "sg:person.01030752312.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030752312.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.430387.b", 
          "name": [
            "Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rosen", 
        "givenName": "R C", 
        "id": "sg:person.01344661236.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344661236.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Advanced Biomedical Research, Pennington, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Advanced Biomedical Research, Pennington, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Willett", 
        "givenName": "M S", 
        "id": "sg:person.0663411625.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663411625.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Palatin Technologies, Inc., Cranbury, New Jersey, USA", 
          "id": "http://www.grid.ac/institutes/grid.423353.0", 
          "name": [
            "Palatin Technologies, Inc., Cranbury, New Jersey, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Molinoff", 
        "givenName": "P B", 
        "id": "sg:person.01222130054.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222130054.96"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.ijir.3900857", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008525079", 
          "https://doi.org/10.1038/sj.ijir.3900857"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ijir.3900443", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035004050", 
          "https://doi.org/10.1038/sj.ijir.3900443"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.ijir.3900831", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042293173", 
          "https://doi.org/10.1038/sj.ijir.3900831"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2004-01", 
    "datePublishedReg": "2004-01-01", 
    "description": "PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan\u2122 in healthy subjects without visual sexual stimulation (VSS) and in Viagra\u00ae-responsive ED patients with VSS. In healthy subjects, mean Cmax and AUC(0\u2013t) increased in a dose-dependent manner. Median Tmax was 0.50\u2009h and mean t1/2 ranged from 1.85 to 2.09\u2009h. In both studies, an erectile response induced by PT-141 administration was statistically significant, compared to placebo, at doses greater than 7\u2009mg, with the onset of the first erection occurring in approximately 30\u2009min. PT-141 was safely administered and well tolerated in both studies. A maximum-tolerated dose was not identified. Flushing and nausea were the most common adverse events reported in both studies and no clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed. Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.ijir.3901139", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1100393", 
        "issn": [
          "0955-9930", 
          "1476-5489"
        ], 
        "name": "International Journal of Impotence Research", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "visual sexual stimulation", 
      "erectile response", 
      "healthy subjects", 
      "placebo-controlled evaluation", 
      "maximum-tolerated dose", 
      "common adverse events", 
      "erectile dysfunction patients", 
      "moderate erectile dysfunction", 
      "melanocortin receptor agonists", 
      "healthy male subjects", 
      "dose-dependent manner", 
      "erectogenic potential", 
      "tolerability profile", 
      "median tmax", 
      "adverse events", 
      "ED patients", 
      "erectile dysfunction", 
      "pharmacodynamic effects", 
      "dysfunction patients", 
      "intranasal administration", 
      "physical exam", 
      "receptor agonist", 
      "healthy males", 
      "PT-141", 
      "male ED", 
      "melanocortin analog", 
      "male subjects", 
      "vital signs", 
      "further evaluation", 
      "sexual stimulation", 
      "patients", 
      "pharmacokinetic properties", 
      "first erection", 
      "administration", 
      "significant changes", 
      "subjects", 
      "laboratory tests", 
      "placebo", 
      "nausea", 
      "dysfunction", 
      "agonists", 
      "mild", 
      "RigiScan", 
      "Cmax", 
      "doses", 
      "dose", 
      "response", 
      "study", 
      "stimulation", 
      "ECG", 
      "treatment", 
      "t1/2", 
      "evaluation", 
      "signs", 
      "onset", 
      "erection", 
      "males", 
      "exam", 
      "ED", 
      "safety", 
      "Tmax", 
      "min", 
      "Viagra", 
      "events", 
      "test", 
      "effect", 
      "manner", 
      "changes", 
      "profile", 
      "candidates", 
      "analogues", 
      "promising candidate", 
      "potential", 
      "properties", 
      "cyclic heptapeptide melanocortin analog", 
      "heptapeptide melanocortin analog", 
      "Viagra-responsive erectile dysfunction (ED) patients", 
      "PT-141 administration", 
      "intranasal PT-141"
    ], 
    "name": "Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction", 
    "pagination": "51-59", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1039312960"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.ijir.3901139"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "14963471"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.ijir.3901139", 
      "https://app.dimensions.ai/details/publication/pub.1039312960"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:16", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_391.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.ijir.3901139"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901139'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901139'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901139'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.ijir.3901139'


 

This table displays all metadata directly associated to this object as RDF triples.

247 TRIPLES      22 PREDICATES      124 URIs      113 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.ijir.3901139 schema:about N04192b10feff4f04b84c87c10181c109
2 N07a9680159e9485da5993800c406b036
3 N2892e2117a254871acdc679a96ceaf67
4 N53f3e630b4764fe188d6b0401a2d4658
5 N60704282e4f24ea49002a33cf0eab5b6
6 N7f9c9bddba0e4cc8bb4f1b8027895965
7 N9320bcfdb2a243689d6a09c1c9378ece
8 N9bd34081b11a45c19525bf3874e575de
9 Na7c15ecf8a114db7978c717e21a4d139
10 Nadb60da7e843450295b17e987cdccedb
11 Nb62208f5544c4149964ae3354d527f3f
12 Ncedfff05745848808f28d64544ab8a5a
13 Nd719439e67c74ddfb3c9c20b21463b26
14 Nf2e966a7e45b4fab91538d37f1b6dd4f
15 Nfc4c01213bdc4ff8a8ea973418a069a4
16 anzsrc-for:11
17 anzsrc-for:1103
18 schema:author N1118cb29509a47a294b880055457465b
19 schema:citation sg:pub.10.1038/sj.ijir.3900443
20 sg:pub.10.1038/sj.ijir.3900831
21 sg:pub.10.1038/sj.ijir.3900857
22 schema:datePublished 2004-01
23 schema:datePublishedReg 2004-01-01
24 schema:description PT-141, a cyclic heptapeptide melanocortin analog, was evaluated following intranasal administration in healthy male subjects and in Viagra-responsive erectile dysfunction (ED) patients. Erectile response was assessed by RigiScan™ in healthy subjects without visual sexual stimulation (VSS) and in Viagra®-responsive ED patients with VSS. In healthy subjects, mean Cmax and AUC(0–t) increased in a dose-dependent manner. Median Tmax was 0.50 h and mean t1/2 ranged from 1.85 to 2.09 h. In both studies, an erectile response induced by PT-141 administration was statistically significant, compared to placebo, at doses greater than 7 mg, with the onset of the first erection occurring in approximately 30 min. PT-141 was safely administered and well tolerated in both studies. A maximum-tolerated dose was not identified. Flushing and nausea were the most common adverse events reported in both studies and no clinically significant changes in vital signs, laboratory tests, ECGs, or physical exams were observed. Based upon its erectogenic potential and tolerability profile, PT-141 is a promising candidate for further evaluation as a treatment for male ED.
25 schema:genre article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N1f63cafbf22d45b98a2dd7de64f7f763
29 N790d1443b3e542858613cf09b6902362
30 sg:journal.1100393
31 schema:keywords Cmax
32 ECG
33 ED
34 ED patients
35 PT-141
36 PT-141 administration
37 RigiScan
38 Tmax
39 Viagra
40 Viagra-responsive erectile dysfunction (ED) patients
41 administration
42 adverse events
43 agonists
44 analogues
45 candidates
46 changes
47 common adverse events
48 cyclic heptapeptide melanocortin analog
49 dose
50 dose-dependent manner
51 doses
52 dysfunction
53 dysfunction patients
54 effect
55 erectile dysfunction
56 erectile dysfunction patients
57 erectile response
58 erection
59 erectogenic potential
60 evaluation
61 events
62 exam
63 first erection
64 further evaluation
65 healthy male subjects
66 healthy males
67 healthy subjects
68 heptapeptide melanocortin analog
69 intranasal PT-141
70 intranasal administration
71 laboratory tests
72 male ED
73 male subjects
74 males
75 manner
76 maximum-tolerated dose
77 median tmax
78 melanocortin analog
79 melanocortin receptor agonists
80 mild
81 min
82 moderate erectile dysfunction
83 nausea
84 onset
85 patients
86 pharmacodynamic effects
87 pharmacokinetic properties
88 physical exam
89 placebo
90 placebo-controlled evaluation
91 potential
92 profile
93 promising candidate
94 properties
95 receptor agonist
96 response
97 safety
98 sexual stimulation
99 significant changes
100 signs
101 stimulation
102 study
103 subjects
104 t1/2
105 test
106 tolerability profile
107 treatment
108 visual sexual stimulation
109 vital signs
110 schema:name Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
111 schema:pagination 51-59
112 schema:productId N284caaf7afa042ecb23ffff5be5fa279
113 N4315474ebfdb4fefbe2d2f18a70af5e5
114 Nebd007de21c6462182d4af1057fad678
115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039312960
116 https://doi.org/10.1038/sj.ijir.3901139
117 schema:sdDatePublished 2021-12-01T19:16
118 schema:sdLicense https://scigraph.springernature.com/explorer/license/
119 schema:sdPublisher N6511a1b2c1b34648b252a795ccd846ed
120 schema:url https://doi.org/10.1038/sj.ijir.3901139
121 sgo:license sg:explorer/license/
122 sgo:sdDataset articles
123 rdf:type schema:ScholarlyArticle
124 N04192b10feff4f04b84c87c10181c109 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Penile Erection
126 rdf:type schema:DefinedTerm
127 N07a9680159e9485da5993800c406b036 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Severity of Illness Index
129 rdf:type schema:DefinedTerm
130 N1118cb29509a47a294b880055457465b rdf:first sg:person.0762637112.91
131 rdf:rest Ncb0ef0a804c14ca2972d08b81197c8cc
132 N126e5f2aa6b745b9894cac97049e9264 rdf:first sg:person.01222130054.96
133 rdf:rest rdf:nil
134 N1f63cafbf22d45b98a2dd7de64f7f763 schema:issueNumber 1
135 rdf:type schema:PublicationIssue
136 N284caaf7afa042ecb23ffff5be5fa279 schema:name pubmed_id
137 schema:value 14963471
138 rdf:type schema:PropertyValue
139 N2892e2117a254871acdc679a96ceaf67 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Male
141 rdf:type schema:DefinedTerm
142 N4315474ebfdb4fefbe2d2f18a70af5e5 schema:name dimensions_id
143 schema:value pub.1039312960
144 rdf:type schema:PropertyValue
145 N52717c6d2f1045708d2ff894c080631d rdf:first sg:person.01344661236.13
146 rdf:rest N85178c25640340e1a93c20085be43e9f
147 N53f3e630b4764fe188d6b0401a2d4658 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Adult
149 rdf:type schema:DefinedTerm
150 N60704282e4f24ea49002a33cf0eab5b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Administration, Intranasal
152 rdf:type schema:DefinedTerm
153 N6511a1b2c1b34648b252a795ccd846ed schema:name Springer Nature - SN SciGraph project
154 rdf:type schema:Organization
155 N790d1443b3e542858613cf09b6902362 schema:volumeNumber 16
156 rdf:type schema:PublicationVolume
157 N7f9c9bddba0e4cc8bb4f1b8027895965 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name alpha-MSH
159 rdf:type schema:DefinedTerm
160 N85178c25640340e1a93c20085be43e9f rdf:first sg:person.0663411625.78
161 rdf:rest N126e5f2aa6b745b9894cac97049e9264
162 N9320bcfdb2a243689d6a09c1c9378ece schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Double-Blind Method
164 rdf:type schema:DefinedTerm
165 N9bd34081b11a45c19525bf3874e575de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Placebos
167 rdf:type schema:DefinedTerm
168 Na7c15ecf8a114db7978c717e21a4d139 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Humans
170 rdf:type schema:DefinedTerm
171 Nadb60da7e843450295b17e987cdccedb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Erectile Dysfunction
173 rdf:type schema:DefinedTerm
174 Nb62208f5544c4149964ae3354d527f3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Receptors, Melanocortin
176 rdf:type schema:DefinedTerm
177 Ncb0ef0a804c14ca2972d08b81197c8cc rdf:first sg:person.01030752312.81
178 rdf:rest N52717c6d2f1045708d2ff894c080631d
179 Ncedfff05745848808f28d64544ab8a5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Middle Aged
181 rdf:type schema:DefinedTerm
182 Nd719439e67c74ddfb3c9c20b21463b26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Peptides, Cyclic
184 rdf:type schema:DefinedTerm
185 Nebd007de21c6462182d4af1057fad678 schema:name doi
186 schema:value 10.1038/sj.ijir.3901139
187 rdf:type schema:PropertyValue
188 Nf2e966a7e45b4fab91538d37f1b6dd4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Treatment Outcome
190 rdf:type schema:DefinedTerm
191 Nfc4c01213bdc4ff8a8ea973418a069a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Adolescent
193 rdf:type schema:DefinedTerm
194 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
195 schema:name Medical and Health Sciences
196 rdf:type schema:DefinedTerm
197 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
198 schema:name Clinical Sciences
199 rdf:type schema:DefinedTerm
200 sg:journal.1100393 schema:issn 0955-9930
201 1476-5489
202 schema:name International Journal of Impotence Research
203 schema:publisher Springer Nature
204 rdf:type schema:Periodical
205 sg:person.01030752312.81 schema:affiliation grid-institutes:grid.423353.0
206 schema:familyName Earle
207 schema:givenName D C
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01030752312.81
209 rdf:type schema:Person
210 sg:person.01222130054.96 schema:affiliation grid-institutes:grid.423353.0
211 schema:familyName Molinoff
212 schema:givenName P B
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222130054.96
214 rdf:type schema:Person
215 sg:person.01344661236.13 schema:affiliation grid-institutes:grid.430387.b
216 schema:familyName Rosen
217 schema:givenName R C
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344661236.13
219 rdf:type schema:Person
220 sg:person.0663411625.78 schema:affiliation grid-institutes:None
221 schema:familyName Willett
222 schema:givenName M S
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663411625.78
224 rdf:type schema:Person
225 sg:person.0762637112.91 schema:affiliation grid-institutes:grid.423353.0
226 schema:familyName Diamond
227 schema:givenName L E
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762637112.91
229 rdf:type schema:Person
230 sg:pub.10.1038/sj.ijir.3900443 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035004050
231 https://doi.org/10.1038/sj.ijir.3900443
232 rdf:type schema:CreativeWork
233 sg:pub.10.1038/sj.ijir.3900831 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042293173
234 https://doi.org/10.1038/sj.ijir.3900831
235 rdf:type schema:CreativeWork
236 sg:pub.10.1038/sj.ijir.3900857 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008525079
237 https://doi.org/10.1038/sj.ijir.3900857
238 rdf:type schema:CreativeWork
239 grid-institutes:None schema:alternateName Advanced Biomedical Research, Pennington, New Jersey, USA
240 schema:name Advanced Biomedical Research, Pennington, New Jersey, USA
241 rdf:type schema:Organization
242 grid-institutes:grid.423353.0 schema:alternateName Palatin Technologies, Inc., Cranbury, New Jersey, USA
243 schema:name Palatin Technologies, Inc., Cranbury, New Jersey, USA
244 rdf:type schema:Organization
245 grid-institutes:grid.430387.b schema:alternateName Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
246 schema:name Department of Psychiatry, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, Piscataway, New Jersey, USA
247 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...